Do You Know

03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *

Products » Items » Uromitexan Injectable 400mg


Contraindicated

Contraindicated
Uromitexan Injectable 400mg :
Type Medicine Authorised
Originator B
Agent Abela Freres
Distributor Abela Freres
Laboratory Baxter
Responsible Party Baxter Oncology GmbH
Origin Germany
Manufacturer Baxter Oncology GmbH
Origin Germany
ATC V03AF01
Revision Date 01/01/2002

Your comment will appear shortly after approval

Uromitexan Injectable 400mg :

Revision Date : 01/10/2014


Effect Frequency
Abdominal pain Very Common
Activated partial thromboplastin time prolonged Not known
Anaphylaxis Not known
Angioedema (Angioneurotic oedema) (Quincke oedema) Not known
Arthralgia (Pain joint) (Joint ache) Common
Asthenia Not known
Back pain Common
Blistering Not known
Bronchospasm Common
Bullae Not known
Burning sensation Not known
Chest pain Common
Conjunctivitis Common
Constipation Common
Cough Common
Decreased appetite Common
Dehydration Common
Diarrhoea (Diarrhea) Very Common
Dizziness Common
Drowsiness Very Common
Drug eruption Not known
Dry mouth (Xerostomia) Common
Dyspnoea (dyspnea) Common
Dysuria (Micturition painful) Common
Epigastralgia (Epigastric pain) Common
Epigastric burning Common
Epistaxis (Nasal bleeding) Common
Erythema Not known
Erythema multiforme Not known
Face oedema Not known
Fatigue Common
Flatulence Common
Flushing Very Common
Gingival bleeding (Gingival hemorrhage) Common
Headache Very Common
Hyperaesthesia Common
Hyperhidrosis Common
Hypersensitivity Not known
Hypoesthesia Common
Hypotension Not known
Hypoxia Not known
Impairment of attention Common
Influenza-like illness Very Common
Infusion site erythema Common
Infusion site pain Common
Infusion site pruritus Very Common
Infusion site rash Very Common
Infusion site reactions Very Common
Infusion site swelling Common
Infusion site urticaria Common
Insomnia Common
Jaw pain Common
Laryngeal discomfort Common
Lethargy Very Common
Lightheadedness Very Common
Lymphadenopathy Common
Malaise Common
Mucosal irritation Common
Myalgia Common
Nasal congestion Common
Nausea Very Common
Nightmares Common
Oedema peripheral Not known
Pain in extremity (Pain in limb) Common
Palpitations Common
Paraesthesia (paresthesia) Common
Photophobia Common
Pleuritic pain Common
Pruritus Common
Pyrexia Very Common
Renal failure acute (Acute renal insufficiency) (Kidney failure acute) (Renal insufficiency acute) Not known
Respiratory distress Not known
Rigors Common
Skin rash Very Common
Syncope Common
Tachycardia Not known
Transaminases increased Common
Urticaria Not known
Vision blurred Common
Vomiting Common

Different Units By MoH Code

Revision Date : no date

Uromitexan Injectable 400mg  MoH 518 :
Form Solution for injection
Packaging Ampoules
Package Size 15x4ml
Strength 400mg
Storage Condition <25°C None
Public Price 2647700,06 L.L.
Stratum B
NSSF ✔
Quarantine ✔
Reg. Number 27480
Submission date 01/01/1993
Registration Year 1993


Price Comparison

● Country: Abu Dhabi
● Package Size: 1x4ml
● Public Price: 132.25 AED ( 543,674.46 LBP )
● Pack size unit used: 1
● Cost/Unit: 132,25 AED ( 542,646.72 LBP )
● Pharmacy Price: 115 AED ( 472760.4 LBP )
● Pricing Date: 27/01/2021
● Type: Medicine Authorised

● Country: Finland
● Package Size: 15x4ml
● Public Price: 295.49 EUR ( 5,431,120.97 LBP )
● Pack size unit used: 15
● Cost/Unit: 19,6993 EUR ( 349,220.95 LBP )
● Reference: Kela
● Pricing Date: 22/04/2021
● Type: Medicine Authorised

● Country: Iceland
● Package Size: 15x4ml
● Public Price: 35251 ISK ( 3,907,925.86 LBP )
● Pack size unit used: 15
● Cost/Unit: 2350,0667 ISK ( 260,521.00 LBP )
● Pharmacy Price: 25345 ISK ( 2809746.7 LBP )
● Reference: Icelandic Medicines Agency
● Pricing Date: 01/04/2020
● Type: Medicine Authorised

● Country: Lebanon
● Form: Solution for injection
● Package Size: 15x4ml
● Public Price: 2647700.06 LBP ( 2,647,700.06 LBP )
● Pack size unit used: 15
● Cost/Unit: 176513,34 LBP ( 176,513.00 LBP )
● Pricing Date: 10/01/2024

● Country: Norway
● Package Size: 15x4ml
● Public Price: 825.6 NOK ( 1,428,510.91 LBP )
● Pack size unit used: 15
● Cost/Unit: 55,04 NOK ( 95,164.85 LBP )
● Pharmacy Price: 619.08 NOK ( 1071175.5516 LBP )
● Reference: Norwegian Medicine Agency
● Pricing Date: 01/04/2020
● Type: Medicine Authorised

● Country: Switzerland
● Package Size: 15x4ml
● Public Price: 82.35 CHF ( 1,404,911.59 LBP )
● Pack size unit used: 15
● Cost/Unit: 5,49 CHF ( 85,301.25 LBP )
● Exfactory Price: 57.46 CHF
● Pricing Date: 04/04/2021
● Type: Medicine Authorised

● Country: UK
● Package Size: 15x4ml
● Public Price: 32.25 GBP ( 649,862.33 LBP )
● Pack size unit used: 15
● Cost/Unit: 2,15 GBP ( 40,301.54 LBP )
● Reference: DMD
● Pricing Date: 08/03/2021
● Type: Medicine Withdrawn

● Country: Cyprus
● Package Size: 15x4ml
● Public Price: 41.35 EUR ( 760,015.07 LBP )
● Pack size unit used: 15
● Cost/Unit: 2,7567 EUR ( 36,760.10 LBP )
● Reference: Cyprus Minister of Health
● Pricing Date: 24/03/2021
● Type: Medicine Authorised

● Country: Belgium
● Package Size: 15x4ml
● Public Price: 36.99 EUR ( 679,878.05 LBP )
● Pack size unit used: 15
● Cost/Unit: 2,466 EUR ( 36,760.10 LBP )
● Reference: cbip
● Pricing Date: 27/11/2020
● Type: Medicine Authorised

● Country: Turkey
● Package Size: 15
● Public Price: 225.5 TRY ( 433,115.60 LBP )
● Pack size unit used: 15
● Cost/Unit: 15,0333 TRY ( 28,810.35 LBP )
● Pricing Date: 28/10/2020
● Type: Medicine Authorised

● Country: KSA
● Package Size: 4ml
● Public Price: 97.2 SAR ( 391,752.94 LBP )
● Pack size unit used: 15
● Cost/Unit: 6,48 SAR ( 24,182.28 LBP )
● Reference: sfda
● Pricing Date: 16/01/2021
● Type: Medicine Authorised

● Country: Jordan
● Package Size: 15
● Public Price: 18.69 JOD ( 398,848.15 LBP )
● Pack size unit used: 15
● Cost/Unit: 1,246 JOD ( 21,340.19 LBP )
● Reference: JFDA
● Pricing Date: 02/01/2021
● Type: Medicine Authorised

● Country: Italy
● Package Size: 15x4ml
● Public Price: 29.66 EUR ( 545,152.28 LBP )
● Pack size unit used: 15
● Cost/Unit: 1,9773 EUR ( 18,380.05 LBP )
● Pricing Date: 17/12/2019
● Type: Medicine Authorised

● Country: Greece
● Package Size: 15x4ml
● Reference: National Organization for Medicines
● Pricing Date: 25/03/2019
● Type: Medicine Non Marketed

● Country: Germany
● Package Size: 15x4ml
● Medica Comments: Not available in the country of origin
● Pricing Date: 20/10/2020
● Type: Medicine not available

● Country: Portugal
● Package Size: 50x4ml
● Reference: Autoridade Nacional do Medicamento e Produtos de Saúde
● Pricing Date: 22/04/2019

● Country: France
● Package Size: 15x4ml
● Reference: ansm
● Pricing Date: 15/05/2021
● Type: Medicine Authorised

● Country: New Zealand
● Package Size: 15 inj
● Exfactory Price: 177.45 NZD
● Reference: New Zealand Pharmaceutical Management Agency
● Pricing Date: 01/04/2020
● Type: Medicine Authorised

    ◼ Lebanon
    ◼ Country of Origin
    ◼ Reference Countries
    ◼ Other Countries

Note

Prevention of urothelial toxicity due to oxazaphosphorines : (Adults)
● Cost/Unit: 132,25 AED ( 542,646.72 LBP )
● Cost/Day: 132,25 AED ( 542,646.72 LBP )
● Cost/Month: 132,25 AED ( 542,646.72 LBP )
Prevention of urothelial toxicity due to oxazaphosphorines : (Adults)
● Cost/Unit: 19,6993 EUR ( 349,220.95 LBP )
● Cost/Day: 19,7 EUR ( 349,220.95 LBP )
● Cost/Month: 19,7 EUR ( 349,220.95 LBP )
Prevention of urothelial toxicity due to oxazaphosphorines : (Adults)
● Cost/Unit: 2350,0667 ISK ( 260,521.00 LBP )
● Cost/Day: 2350,07 ISK ( 260,521.00 LBP )
● Cost/Month: 2350,07 ISK ( 260,521.00 LBP )
Prevention of urothelial toxicity due to oxazaphosphorines : (Adults)
● Cost/Unit: 176513,34 LBP ( 176,513.00 LBP )
● Cost/Day: 176513,34 LBP ( 176,513.00 LBP )
● Cost/Month: 176513,34 LBP ( 176,513.00 LBP )
Prevention of urothelial toxicity due to oxazaphosphorines : (Adults)
● Cost/Unit: 55,04 NOK ( 95,164.85 LBP )
● Cost/Day: 55,04 NOK ( 95,164.85 LBP )
● Cost/Month: 55,04 NOK ( 95,164.85 LBP )
Prevention of urothelial toxicity due to oxazaphosphorines : (Adults)
● Cost/Unit: 5,49 CHF ( 85,301.25 LBP )
● Cost/Day: 5,49 CHF ( 85,301.25 LBP )
● Cost/Month: 5,49 CHF ( 85,301.25 LBP )
Prevention of urothelial toxicity due to oxazaphosphorines : (Adults)
● Cost/Unit: 2,15 GBP ( 40,301.54 LBP )
● Cost/Day: 2,15 GBP ( 40,301.54 LBP )
● Cost/Month: 2,15 GBP ( 40,301.54 LBP )
Prevention of urothelial toxicity due to oxazaphosphorines : (Adults)
● Cost/Unit: 2,466 EUR ( 36,760.10 LBP )
● Cost/Day: 2,47 EUR ( 36,760.10 LBP )
● Cost/Month: 2,47 EUR ( 36,760.10 LBP )
Prevention of urothelial toxicity due to oxazaphosphorines : (Adults)
● Cost/Unit: 2,7567 EUR ( 36,760.10 LBP )
● Cost/Day: 2,76 EUR ( 36,760.10 LBP )
● Cost/Month: 2,76 EUR ( 36,760.10 LBP )
Prevention of urothelial toxicity due to oxazaphosphorines : (Adults)
● Cost/Unit: 15,0333 TRY ( 28,810.35 LBP )
● Cost/Day: 15,03 TRY ( 28,810.35 LBP )
● Cost/Month: 15,03 TRY ( 28,810.35 LBP )
Prevention of urothelial toxicity due to oxazaphosphorines : (Adults)
● Cost/Unit: 6,48 SAR ( 24,182.28 LBP )
● Cost/Day: 6,48 SAR ( 24,182.28 LBP )
● Cost/Month: 6,48 SAR ( 24,182.28 LBP )
Prevention of urothelial toxicity due to oxazaphosphorines : (Adults)
● Cost/Unit: 1,246 JOD ( 21,340.19 LBP )
● Cost/Day: 1,25 JOD ( 21,340.19 LBP )
● Cost/Month: 1,25 JOD ( 21,340.19 LBP )
Prevention of urothelial toxicity due to oxazaphosphorines : (Adults)
● Cost/Unit: 1,9773 EUR ( 18,380.05 LBP )
● Cost/Day: 1,98 EUR ( 18,380.05 LBP )
● Cost/Month: 1,98 EUR ( 18,380.05 LBP )
Prices are provided in Dollar ($)
You have to register to view this info

You have to register to view this info

You have to register to view this info